http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2363998-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate | 2008-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_059b1af98df615161fddd05a8f2adc32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83c1f7ef6e14ab3964ef18b1569ab988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46a36bf59ac239d9dcdfec964082545a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_742576cc9ae853ae3c97cef82a9e8d37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dd5a9a03df8e393c24374f1d2204172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bc0d34a1175ee1137c2f7bfe297fb32 |
| publicationDate | 2011-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2363998-T3 |
| titleOfInvention | ESTER DERIVATIVES AND CARBAMATE OF AZAADAMANTAN AND METHODS OF USE OF THE SAME. |
| abstract | A compound of formula (I) ** Formula ** where Y1 is A, -N (RX-A, or -C (RY) = C (R) ZA; with the proviso that Y1 is different from benzothien-3- unsubstituted yl or 4-chlorophenyl; A is aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, or heterocycloalkyl, where aryl, heteroaryl, heterocycle, aryl alkyl aryl, heteroaryl heteroaryl alkyl radical, and heterocycloalkyl heterocycle radical each independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, cyano, oxo, methylenedioxy, ethylenedioxy, G1, -NO2, -OR1a, -OC (O) R1a, -OC (O) N (Rb) (R3a), -SR1a, -S (O) 2R2a, -S (O) 2N (Rb) (R3a), -C (O) R1a, -C (O) OR1a, C (O) N (Rb) (R3a), -N (Rb) (R3a), -N (Ra) C (O) R1a, -N (Ra) S (O) R2a, -N (Ra) C (O) O (R1a), -N (Ra) C (O) N (Rb) (R3a), - (CRa4R5a) mNO2, - (CR4aR5a) m-OR1a, - (CR4aR5a) m-OC (O) R1a, - (CR4aR5a) m-OC (O) N (Rb) (R3a), - (CR4aR5a) m-SR1a, - (CR4aR5a) m15 S (O) 2R2a, - (CR4aR5a) mS (O) 2 N (Rb) (R3a), - (CR4aRa) mC (O) R1a, - (CR4aR5a) mC (O) OR1a, - (CR4aR5a) mC (O) N (Rb) (R3a), (CR4aR5a) mN (Rb ) (R3a), - (CR4aR5a) mN (Ra) C (O) R1a, - (CR4aR5a) mN (Ra) S (O) 2R2a, - (CR4aR5a) mN (Ra) C (O) O (R1a), (CR4aR5a) mN (Ra) C (O) N (Rb) (R3a), - (CR4aR5a) m-G1, cyanoalkyl, and haloalkyl; where R1a and R3a, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, G1, or - (CR6R7) n-O1; R2a, at each occurrence, is independently alkyl, haloalkyl, G1, or - (CR6R7) n-G1; R4a, R5a, R6, and R7, at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl; Ra and Rb, at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; m and n, at each occurrence, are each independently 1, 2, 3, 4, or 5; G1 is aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, where each G1 is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, cyano, oxo, methylenedioxy, ethylenedioxy, -NO2, -OR1b, -OC (O) R1b, -OC (O) N (Rb) (R3b), -SR1b, S (O) 2R2b, -S (O) 2N (Rb) (R3b ), -C (O) R1b, -C (O) OR1b, -C (O) N (Rb) (R3b), -N (Rb) (R3b), -N (Ra) C (O) R1b, - N (Ra) S (O) 2R2b, N (Ra) C (O) O (R1b), -N (Ra) C (O) N (Rb) (R3b), - (CR4bR5b) m-NO2, - ( CR4bR5b) m-OR1b, - (CR4bR5bs) m-OC (O) R1b, - (CR4bR5b) mOC (O) N (Rb) (R3b), - (CR4bR5b) m-SR1b, - (CR4bR5b) mS (O) 2R2b, - (CR4bR5a) mS (O) 2N (Rb) (R3b), - (CR4bR5b) mC (O) R1b, (CR4bR5b) mC (O) OR1b, - (CR4bR5a) mC (O) N (Rb) ( R3b), - (CR4bR5b) mN (Rb) (R3b), - (CR4bR5b) mN (Ra) C (O) R1b, - (CR4bR5b) m30 N (Ra) S (O) 2R2b, - (CR4bR5b) mN ( Ra) C (O) O (R1b), - (CR4bR5a) mN (Ra) C (O) N (Rb) (R3b), cyanoalkyl, and haloalkyl; R1b and R3b, at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; R2b, at each occurrence, is independently alkyl or haloalkyl; and R4b and R5b, at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl; and RX, RY, and RZ, at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; or one of its pharmaceutically acceptable salts; where the alkenyl is a linear or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond; and where the alkynyl is a linear or branched hydrocarbon chain group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond; and where the cycloalkyl is a monocyclic, bicyclic, or tricyclic cycloalkyl, where the monocyclic cycloalkyl is a monocyclic carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds, where the bicyclic cycloalkyl is a fused monocyclic cycloalkyl. to a monocyclic cycloalkyl ring, or a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are connected by means of an alkylene bridge of one, two, three, or four carbon atoms, and where the tricyclic cycloalkyl is a bicyclic cycloalkyl fused to a monocyclic cycloalkyl, or a bridged bicyclic cycloalkyl in which two non-adjacent carbon atoms of the bicyclic ring system are connected by means of an alkylene bridge of between one and four carbon atoms; and where the cycloalkenyl is monocyclic or bicyclic, where the monocyclic cycloalkenyl has four, five, six, seven, or eight carbon atoms and zero heteroatoms, where the four-membered monocyclic cycloalkenyl has a double bond, the five-membered monocyclic cycloalkenyl has one or two double bonds, the six-membered monocyclic cycloalkenyl has one or two double bonds, the seven-member monocyclic cycloalkenyl has one, two or three double bonds, and the eight-member monocyclic cycloalkenyl has one, two or three double bonds, and where the bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group, and where the monocyclic or bicyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, three, or four carbon atoms and connecting two atoms each carbon not adjacent to the ring. |
| priorityDate | 2007-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 310.